Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Jul 23, 2018 11:00am
370 Views
Post# 28352781

What its worth

What its worthSome are playing actually that TH will go down. "Under 10$, sad....".

Like our friend CANDIDE who sold all his position at 9$ after approval, a lot of folks, say goodbye to early, and are waiting to step back in when signs will appear that a bullish period is back. That is their choice.

Actually stock market around TH looks a lot like the period just before approval. We all know great news are coming for this company, but when ? Some came in playing with AUGUST and that they knew a lot about this story......others think that fall will be exciting. And maybe that 2018 will stay relatively even for TH ? Who really knows ?

But facts are facts, and we, shareholders, will have answers shortly in regards of those questions, partly because TANGUAY made it clear (Trogarzo sales will rapidly beat EGRIFTA numbers and that he his looking to buy new products to sell before 2019):

1. trend and sales numbers of TROGARZO (it seems that we are looking at the good scenario presented by SPCEO, but we all can be surprise with a take-off in this quarter in regards of sales);
2. Acquisitions;
3. first profits for the company opening a period of prosperity and attracting new investors.

Stock price will react to those informations to come.

FTV.
Bullboard Posts